Innovent Biologics said China’s National Medical Products Administration (NMPA) has approved its biosimilar bevacizumab, Byvasda, for use in patients with lung and colorectal cancers.
Suzhou, China-based Innovent Biologics said China’s National Medical Products Administration (NMPA) has approved its biosimilar bevacizumab, Byvasda, for marketing for the treatment of advanced non—small cell lung cancer (NSCLC) and metastatic colorectal cancer.
"The launch of Byvasda will provide Chinese patients with high-quality and relatively more-affordable bevacizumab," Innovent said in a statement. The company noted that cancer incidence for the drug's indications is high and the cost of the reference product is beyond the reach of many patients.
The competition to bring bevacizumab biosimilars to market in China is heating up. Also this week, Shanghai Henlius Biotech said its bevacizumab biosimilar candidate HLX04 met the 9-month primary end point of progression-free survival in patients with metastatic colorectal cancer (mCRC).
Henlius said the drug is being developed specifically for use in treating mCRC and nonsquamous NSCLC.
“Currently, there still remains huge unmet clinical demand for bevacizumab treatment in China, as many ordinary Chinese patients cannot afford it,” Innovent said.
Among malignant tumors, lung cancer has the highest incidence and mortality rate in China, with more than 770,000 newly diagnosed patients and 690,000 deaths in 2018, according to a report from the World Health Organization (WHO)'s International Agency for Cancer Research.
Also in China in 2018, there were 517 million patients with newly diagnosed colorectal cancer and 245 million deaths from this disease, according to the WHO.
Bevacizumab is a recombinant humanized anti—vascular endothelial growth factor monoclonal antibody (mAb) drug and is used to treat patients with multiple malignant tumors globally, including NSCLC, mCRC, glioblastoma, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The bevacizumab biosimilar references Genentech’s Avastin and is Innovent’s second mAb drug approved by the NMPA in China following a sintilimab (Tyvyt) injectable approved in 2018 for patients with Hodgkin lymphoma.
In January 2020, Innovent sold the US and Canadian commercialization rights for Byvasda to Coherus BioSciences, of Redwood City, California.
Innovent has rituximab (IBI301) and adalimumab (IBI303) biosimilars in development. A phase 3 trial of IB301 concluded in 2019 and results showed that safety and pharmacokinetic data demonstrated equivalency to the reference drug, Rituxan. IBI303 is currently under review by the NMPA after an application for this was accepted in 2018.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.